دورية أكاديمية

Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes "RIO".

التفاصيل البيبلوغرافية
العنوان: Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes "RIO".
Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies
المؤلفون: Scheen, André, Van Gaal, L. G., Despres, J. P., Pi-Sunyer, X., Golay, A., Hanotin, C.
المصدر: Revue Médicale Suisse, 2 (76), 1916-23 (2006)
بيانات النشر: Medecine et Hygiène, 2006.
سنة النشر: 2006
مصطلحات موضوعية: Anti-Obesity Agents/therapeutic use, Humans, Metabolic Syndrome X/prevention & control, Obesity/drug therapy, Overweight/drug effects, Piperidines/therapeutic use, Pyrazoles/therapeutic use, Randomized Controlled Trials as Topic, Receptors, Cannabinoid/antagonists & inhibitors, Human health sciences, Pharmacy, pharmacology & toxicology, Endocrinology, metabolism & nutrition, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie, Endocrinologie, métabolisme & nutrition
الوصف: RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without comorbidities (RIO-Europe and RIO-North America), with untreated dyslipidaemia (RIO-Lipids) or with type 2 diabetes treated with metformin or sulfonylurea (RIO-Diabetes). Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant.
نوع الوثيقة: journal article
http://purl.org/coar/resource_type/c_6501
article
اللغة: French
Relation: http://www.revmed.ch
URL الوصول: https://orbi.uliege.be/handle/2268/12079
حقوق: open access
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
رقم الأكسشن: edsorb.12079
قاعدة البيانات: ORBi